🔬The BioAI Phase Shift - Matthew McPartlon & Neil Patil, Chai Discovery

AI-driven protein design is transforming drug discovery from a slow, trial-and-error process into a precise engineering discipline. Chai Discovery, represented by co-founders Matt McPartland and Neil Patil, leverages generative models to design therapeutic candidates like antibodies with sub-angstrom structural accuracy. This approach replaces traditional, expensive "waterfall" development cycles with agile, iterative loops, enabling the creation of complex molecules such as agonists and bi-specifics that were previously difficult to target. By functioning as a neutral software factory, the platform allows pharmaceutical partners to address intractable disease targets, effectively reducing the exponentially rising costs of drug development. The shift toward computational, declarative design enables researchers to move beyond experimental guesswork, fostering a new era where therapeutic candidates are engineered with high specificity, stability, and developability from the outset.